Universal CARs can also implement the “OR” logic, as in Cartellieri et al., where a dual-specific anti-CD123-CD33 targeting module, consisting of two scFv connected to a target epitope, interacts with the scFv of a universal CAR, increasing AML cell killing compared to simultaneous administration of single soluble modules [127] (Fig. 1, Table 3). This evidence concerns the gene CD33 and acute myeloid leukemia.